CHEK2 and colorectal carcinoma: On the contrary, no differences were found in CRC-SC response to inhibitors of the other DDR kinases ATM, CHK2 and DNA-PK, which were all less effective than ATR/CHK1 inhibitors (Fig. 1e; Supplementary Fig. S1f).